Clinical Trials

Pivotal Study to Evaluate Perimeter’s Next Generation OCT Imaging Platform

Recognizing the unmet need in the field of breast cancer margin visualization, Perimeter has a randomized, controlled, multi-site, pivotal study underway with approximately 300 patients. Perimeter’s objective is to evaluate Perimeter B-Series OCT2 with ImgAssist AI against the current standard of care and assess the impact of our margin visualization technology on re-operation rates for patients undergoing breast conservation surgery. This randomized control trial (RCT) is expected to be completed in late 2022, representing the next generation of Perimeter’s commercially available flagship S-Series OCT.


Perimeter is proud to partner with leading breast surgeons and cancer centers, including:

  • West Cancer Center, Germantown, TN
  • Baylor College of Medicine, Houston, TX
  • Methodist Healthcare/Start Cancer Center, San Antonio, TX
  • Holy Redeemer Hospital, Meadowbrook, PA
  • University of Wisconsin, Madison, WI
  • St. David’s HealthCare, Austin, TX
  • Moffitt Cancer Center, Tampa, FL
  • Medical City Healthcare, Dallas, TX

Perimeter’s artificial intelligence technology has the potential to be a powerful intraoperative tool for identifying regions of interest to help surgeons make real-time decisions on margin status in the OR. The goal is to determine whether this technology can help lower re-excision rates – potentially setting a new standard for specimen imaging technology during breast conservation surgery.

Alastair Thompson_Baylor College of Medicine

Clinical Trial Milestones

February 2022

Dr. Alastair Thompson from Baylor College of Medicine in Houston, TX, enrolls the first clinical study subject into the trial.

January 2022

Clinical trial expands to include Baylor College of Medicine in Houston, TX, under the direction of Dr. Alastair Thompson, who is Principal Investigator of the study.

December 2021

Perimeter announces initiation of first clinical trial site at West Cancer Center & Research Institute in Tennessee.

November 2021

Perimeter receives approval from the U.S. FDA for an Investigational Device Exemption (IDE)  to support the launch of the pivotal study. Trial start-up activities get underway at eight sites.

April 2021

U.S. FDA grants Perimeter’s B-Series OCT Breakthrough Device Designation, a program designed to speed up access to disruptive new technologies.

April 2021

ImgAssist is trained with more than 400 volumes of images of excised breast tissue and achieves a 0.94 AUC score (or 94% “predictivity”) of how well the algorithm can differentiate between suspicious and non-suspicious breast tissue areas

July 2020

With the support of a $7.4 million grant from Cancer Prevention and Research Institute of Texas (CPRIT), the ATLAS AI project is launched to collect data from leading cancer centers – including MD Anderson, Baylor College of Medicine and UT Southwestern San Antonio – to train and test the ImgAssist AI algorithm.

Clinical Development Milestones

Learn More

You Might Be Interested In

Clinical Evidence

News & Events

Meet the Team

Ready to learn more about Perimeter?

Get Started